Inotiv (NOTV) Stock Price, News & Analysis

Company Overview

Inotiv, Inc., formerly known as Bioanalytical Systems, Inc. (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support. Inotiv’s facilities are designed to meet stringent regulatory standards and accommodate a wide range of study types, from small molecule and biologic evaluation to specialty services addressing ophthalmology, neuroscience and cardiovascular indications. With laboratory locations in the United States, Europe and Asia Pacific, Inotiv serves a diverse client base seeking scalable, GLP‐compliant research solutions.

Inotiv traces its roots to the founding of Bioanalytical Systems, Inc. in the early 1980s and formally adopted the Inotiv name in 2020 to reflect its broadening suite of scientific services. Headquartered in West Lafayette, Indiana, the company has grown through strategic investments in technology platforms and site expansions. Inotiv is led by a management team with deep expertise in biopharmaceutical research and CRO operations, positioning the company to support clients from target identification through IND filing and beyond.

Key Stats

• Today's Range: $0.26 to $0.29
• 50-Day Range: $0.23 to $0.39
• 52-Week Range: $0.22 to $3.32
• Volume: 945,749 shs
• Average Volume: 732,078 shs
• Market Capitalization: $9.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Hold

Inotiv Stock Analysis - MarketRank™

Inotiv scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Inotiv has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Inotiv has a consensus price target of $1.50, representing about 455.6% upside from its current price of $0.27.

Amount of Analyst Coverage

Inotiv has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Inotiv is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inotiv is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inotiv has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.88% of the float of Inotiv has been sold short.

Short Interest Ratio / Days to Cover

Inotiv has a short interest ratio ("days to cover") of 4.08.

Change versus previous month

Short interest in Inotiv has recently increased by 15.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inotiv does not currently pay a dividend.

Dividend Growth

Inotiv does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Inotiv to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inotiv insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.80% of the stock of Inotiv is held by insiders.

Percentage Held by Institutions

18.17% of the stock of Inotiv is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/24/2026
• Status update: 6/10/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NOTV
• CIK: 720154
• Web: www.inotivco.com
• Phone: (765) 463-4527
• Fax: 765-497-1102
• Employees: 2,046
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Inotiv: $1.50
• High Price Target: $1.50
• Low Price Target: $1.50
• Potential Upside/Downside: +455.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.62 million
• Net Margins: -17.14%
• Pretax Margin: -20.84%
• Return on Equity: -56.77%
• Return on Assets: -8.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.27
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $507.36 million
• Price / Sales: 0.02
• Cash Flow: $0.10 per share
• Price / Cash Flow: 2.79
• Book Value: $2.21 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 34,888,000
• Free Float: 32,167,000
• Market Cap: $9.42 million
• Optionable: Optionable
• Beta: 3.82